

Neuraminidase Inhibitors from the Fruiting Body of *Phellinus igniarius*

Ji-Yul Kim[†], Dae-Won Kim[†], Byung Soon Hwang[†], E-Eum Woo, Yoon-Ju Lee, Kyeong-Woon Jeong, In-Kyoung Lee and Bong-Sik Yun*

Division of Biotechnology and Advanced Institute of Environment and Bioscience, College of Environmental and Bioresource Sciences, Chonbuk National University, Iksan 54596, Korea

Abstract During our ongoing investigation of neuraminidase inhibitors from medicinal fungi, we found that the fruiting bodies of *Phellinus igniarius* exhibited significant inhibitory activity against neuraminidase from recombinant H3N2 influenza viruses. Two active compounds were isolated from the methanolic extract of *P. igniarius* through solvent partitioning and Sephadex LH-20 column chromatography. The active compounds were identified as phelligradins E and G on proton nuclear magnetic resonance (¹H NMR) and electrospray ionization mass measurements. These compounds inhibited neuraminidases from recombinant rH1N1, H3N2, and H5N1 influenza viruses, with IC₅₀ values in the range of 0.7~8.1 μM.

Keywords Neuraminidase inhibitor, Phelligradin E, Phelligradin G, *Phellinus igniarius*

Neuraminidase, also known as sialidase, is an important glycoprotein in influenza viruses that cleaves sialic acid from the infected cell surface and releases virus progeny [1]. It plays a major role in viral proliferation and infecting other cells [2]. Thus, neuraminidase is an attractive therapeutic drug target for the treatment of influenza. Currently, neuraminidase inhibitors such as zanamivir (Relenza; Glaxo Wellcome Inc., Research Triangle Park, NC, USA) and oseltamivir (Tamiflu; Roche, Nutley, NJ, USA) are used for the treatment of influenza. However, several problems are associated with these drugs, including a high level of drug resistance and diverse side effects such as vomiting and nausea [3, 4]. Therefore, next-generation neuraminidase inhibitors are urgently needed.

Mushrooms are both a nutritional food source and a

traditional medicine. They produce various classes of bioactive secondary metabolites with unique chemical structures [5, 6]. In previous studies, we reported the isolation of neuraminidase inhibitors from *Phellinus baumii* and *P. linteus* and their biological properties [7-9]. As part of an ongoing effort to identify neuraminidase inhibitors from medicinal fungi, we found that the methanolic extract of fruiting bodies of *P. igniarius* exhibited significant H3N2 neuraminidase inhibitory activity. *Phellinus igniarius*, belonging to the family Hymenochaetaceae, has been used to treat fester, abdominalgia, and bloody gonorrhoea in traditional medicine in Korea, Japan, and China and has been reported to possess anti-oxidative, anti-proliferative, anti-metastatic, and anti-influenza activities [10-12]. In this study, we describe the isolation, structure determination, and biological properties of neuraminidase inhibitors from the methanolic extract of *P. igniarius*.

Isolation of neuraminidase inhibitors. In order to isolate neuraminidase inhibitors, the fruiting bodies of *P. igniarius* were extracted using methanol for 2 days at room temperature. The methanolic extract was concentrated under reduced pressure, and the resultant residue was partitioned twice with ethyl acetate. The ethyl acetate-soluble layer was subjected to Sephadex LH-20 column chromatography (Pharmacia, Uppsala, Sweden) eluted with methanol to yield two active fractions. One active fraction was further purified by Sephadex LH-20 column chromatography eluted with 70% aqueous methanol to provide compound **1**. The other fraction was subjected to Sephadex LH-20 column chromatography with 70% aqueous methanol as the eluting

Mycobiology 2016 June, 44(2): 117-120
<http://dx.doi.org/10.5941/MYCO.2016.44.2.117>
pISSN 1229-8093 • eISSN 2092-9323
© The Korean Society of Mycology

***Corresponding author**

E-mail: bsyun@jbnu.ac.kr

[†]These authors contributed equally to this work.

Received April 26, 2016

Revised June 1, 2016

Accepted June 1, 2016

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

solvent to yield compound 2.

Structure determination of neuraminidase inhibitors.

The chemical structures of compounds 1 and 2 were determined via electrospray ionization (ESI)-mass and proton nuclear magnetic resonance (^1H NMR) spectrum measurements. The molecular weight of compound 1 was 474 on ESI-mass measurement, where it exhibited a quasi-molecular ion peak at m/z 475 $[\text{M}+\text{H}]^+$. The ^1H NMR spectrum of 1 in $\text{DMSO}-d_6$ demonstrated seven methine




Fig. 1. Chemical structure of compounds 1 (phelligridin E) and 2 (phelligridin G).

Table 1. Neuraminidase inhibitory activity of compounds 1 and 2

Compound	Neuraminidase inhibition (IC_{50} , μM)			Kinetic mode (K_i , μM)
	H1N1	H3N2	H5N1	
Phelligridin E (1)	8.1 ± 0.1	6.6 ± 0.4	1.0 ± 0.3	Noncompetitive (7.1)
Phelligridin G (2)	8.0 ± 1.0	5.2 ± 0.6	0.7 ± 0.1	Noncompetitive (6.9)
Zanamivir (nM)	1.3 ± 0.1	8.0 ± 1.5	3.1 ± 0.1	NT

NT, not tested.




Fig. 2. Graphical representation of the neuraminidase inhibition of isolated compounds. A, B, Lineweaver-Burk plots of the neuraminidase inhibition of compounds 1 and 2; C, D, Dixon plots of the neuraminidase inhibition of compounds 1 and 2.

protons at δ 8.24, 7.85, 7.47, 6.97, 6.61, 6.15, and 6.09 and one methyl signal at δ 2.50. Based on literature review, compound **1** was identified as phelligridin E; the molecular weight and ^1H chemical shift values were in good agreement with those previously reported for phelligridin E [13].

The chemical structure of compound **2** was also determined via ESI-mass and ^1H NMR spectrum measurements. The molecular weight of compound **2** was 594 on ESI-mass measurement, and it demonstrated a quasi-molecular ion peak at m/z 595 $[\text{M}+\text{H}]^+$. The ^1H NMR spectrum of compound **2** in $\text{DMSO}-d_6$ showed three aromatic methine signals assignable to a 1,2,4-trisubstituted benzene moiety at δ 7.17 (d, $J = 2.1$ Hz), 7.10 (dd, $J = 8.2, 2.1$ Hz), and 6.79 (d, $J = 8.2$ Hz), two olefinic methine peaks attributable to a *trans*-1,2-disubstituted double bond at δ 7.54 (d, $J = 16.2$ Hz) and 7.10 (d, $J = 16.2$ Hz), and seven methine singlets at δ 8.28, 7.86, 7.48, 7.01, 6.64, 6.25, and 6.02. These spectral data were consistent with those of phelligridin G previously reported in the literature [14]. Therefore, compounds **1** and **2** were identified as phelligridin E and phelligridin G, respectively, as shown in Fig. 1.

Neuraminidase inhibition activity. The inhibitory activity of compounds **1** and **2** against neuraminidases from recombinant rH1N1, H3N2, and H5N1 influenza viruses was evaluated. Neuraminidase inhibition assay was performed in 96-well plates as previously described [15], with some modifications. Briefly, the substrate, 50 μL of 0.2 mM MUNANA (2-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid sodium salt; Sigma, St. Louis, MO, USA), was mixed with 90 μL of 50 mM Tris buffer (containing 200 mM NaCl, 5 mM CaCl_2 , pH 7.5) at room temperature. Ten microliters of the sample and 50 μL of H1N1 neuraminidase (50 ng/mL) were added to each well. The mixture was then recorded at the excitation and emission wavelengths of 365 nm and 445 nm, respectively, using a POLAR OPTIMA (BMG LABTECH, Ortenberg, Germany). In the case of H3N2 and H5N1 neuraminidases, 25 mM MES buffer (containing 500 mM NaCl, 5 mM CaCl_2 , pH 6.5) and 50 mM MES buffer (containing 500 mM NaCl, 5 mM CaCl_2 , pH 6.5) were used, respectively, and H5N1 required an activation period of 24 hr at 37°C before assay. The other methods were the same as used for H1N1 neuraminidase. A neuraminidase inhibitor, zanamivir (Relenza) was used as a positive control. Compounds **1** and **2** showed H3N2 neuraminidase inhibition activity with an IC_{50} value of 6.7 μM , respectively, in a dose-dependent manner. Inhibitory activity of compounds **1** and **2** against H1N1 and H5N1 neuraminidases were also evaluated. These compounds significantly inhibited the H1N1 and H5N1 neuraminidases with IC_{50} values in the range of 0.8–1.0 μM in a dose-dependent manner (Table 1).

We investigated the inhibition type of compounds **1** and **2** using kinetic parameters. To study the mode of inhibition, Dixon plots were used to distinguish the mechanism of neuraminidase enzyme action and to confirm the inhibition

constant (K_i). The data were measured using Sigmaplot ver. 1.3 (Systat, Chicago, IL, USA). Compounds **1** and **2** displayed noncompetitive inhibitory activity, as indicated by a decrease in V_{max} while K_m remained stable at increasing inhibitor concentrations. The inhibition constant (K_i) values of compounds **1** and **2** were 7.1 ± 0.3 and 6.9 ± 0.3 , respectively (Fig. 2).

ACKNOWLEDGEMENTS

This work was supported by the Technology Development Program for Bio-industry, Ministry for Food, Agriculture, Forestry and Fisheries as well as the Korea Forest Service, Republic of Korea.

REFERENCES

1. Dao TT, Nguyen PH, Lee HS, Kim E, Park J, Lim SI, Oh WK. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from *Glycyrrhiza inflata*. *Bioorg Med Chem Lett* 2011;21:294-8.
2. Brouillette WJ, Baipai SN, Ali SM, Velu SE, Atigadda VR, Lommer BS, Finley JB, Luo M, Air GM. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents. *Bioorg Med Chem* 2003;11:2739-49.
3. Dao TT, Nguyen PH, Won HK, Kim EH, Park J, Won BY, Oh WK. Curcuminoids from *Curcuma longa* and their inhibitory activities on influenza A neuraminidases. *Food Chem* 2012;134:21-8.
4. Li B, Ni Y, Zhu LJ, Wu FB, Yan F, Zhang X, Yao XS. Flavonoids from *Matteuccia struthiopteris* and their anti-influenza virus (H1N1) activity. *J Nat Prod* 2015;78:987-95.
5. Kim SE, Hwang BS, Song JG, Lee SW, Lee IK, Yun BS. New bioactive compounds from Korean native mushrooms. *Mycobiology* 2013;41:171-6.
6. Lindequist U, Niedermeyer TH, Jülich WD. The pharmacological potential of mushrooms. *Evid Based Complement Alternat Med* 2005;2:285-99.
7. Yeom JH, Lee IK, Ki DW, Lee MS, Seok SJ, Yun BS. Neuraminidase inhibitors from the culture broth of *Phellinus linteus*. *Mycobiology* 2012;40:142-4.
8. Hwang BS, Lee MS, Lee SW, Lee IK, Seo GS, Choi HJ, Yun BS. Neuraminidase inhibitors from the fermentation broth of *Phellinus linteus*. *Mycobiology* 2014;42:189-92.
9. Hwang BS, Lee IK, Choi HJ, Yun BS. Anti-influenza activities of polyphenols from the medicinal mushroom *Phellinus baumii*. *Bioorg Med Chem Lett* 2015;25:3256-60.
10. Song TY, Lin HC, Yang NC, Hu ML. Antiproliferative and antimetastatic effects of the ethanolic extract of *Phellinus igniarius* (Linnaeus: Fries) Quélet. *J Ethnopharmacol* 2008; 115:50-6.
11. Wang Y, Wang SJ, Mo SY, Li S, Yang YC, Shi JG. Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus *Phellinus igniarius*. *Org Lett* 2005;7:4733-6.
12. Lee S, Kim JI, Heo J, Lee I, Park S, Hwang MW, Bae JY, Park MS, Park HJ, Park MS. The anti-influenza virus effect of

- Phellinus igniarius* extract. J Microbiol 2013;51:676-81.
13. Mo S, Wang S, Zhou G, Yang Y, Li Y, Chen X, Shi J. Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus *Phellinus igniarius*. J Nat Prod 2004;67:823-8.
 14. Wang Y, Mo SY, Wang SJ, Li S, Yang YC, Shi JG. A unique highly oxygenated pyrano[4,3-c][2]benzopyran-1,6-dione derivative with antioxidant and cytotoxic activities from the fungus *Phellinus igniarius*. Org Lett 2005;7:1675-8.
 15. Kim JY, Jeong HJ, Park JY, Kim YM, Park SJ, Cho JK, Park KH, Ryu YB, Lee WS. Selective and slow-binding inhibition of shikonin derivatives isolated from *Liothospermum erythrorhizon* on glycosyl hydrolase 33 and 34 sialidases. Bioorg Med Chem 2012;20:1740-8.